Sermorelin – A Better Approach to Managing Age-Related Growth Hormone Deficiency
Source: Walker R.F., Clinical Interventions in Aging, 2007, PMC2699646
Purpose of the Article
To discuss the potential of Sermorelin as a more physiological and safer alternative to recombinant human growth hormone (rhGH) in adults with GH deficiency or age-related decline in its secretion.
Background
Traditional rhGH therapy is effective in counteracting somatic aging, but carries several risks:
Improper dosing can cause serious side effects.
Exogenous GH creates non-physiological "square-wave" peaks that are not controlled by feedback mechanisms.
The legal framework restricts rhGH use to specific clinical indications (AIDS or confirmed GHD).
Sermorelin (GHRH 1–29 NH2-acetate) is an analog of the natural hormone that stimulates GH secretion (GHRH), whose levels decline with age. By binding to receptors in the pituitary gland, it activates the endogenous release of GH, mimicking physiological pulsatility.
Key Advantages Over rhGH
Physiological control: Effects are regulated by somatostatin, which prevents overdosing.
Pulsatile secretion: GH release is episodic rather than a sustained peak, as with rhGH.
No tachyphylaxis: Secretion remains responsive to stimuli due to the natural rhythm of release.
Slows aging of the endocrine axis: Helps preserve normal physiology with age.
Legal and Clinical Status
Unlike rhGH, Sermorelin has no federal restrictions on prescribing for adults, allowing clinicians to use it off-label within research protocols evaluating its efficacy and safety.
Conclusion
Sermorelin offers a more physiological approach to GHRT in adults.
It reduces the risk of side effects and maintains natural regulation of the GH/IGF-1 axis.
It can be used as a safe and legal alternative to maintain hormonal balance during aging.